Response to thalidomide in multiple myeloma: Impact of angiogenic factors

Cytokine

Volumn 26, Issue 4, 2004, Pages 145-148

  Rosiñol, Laura ^a   Cibeira, M Teresa ^a   Segarra, Marta ^a   Cid, Maria C ^a   Filella, Xavier ^a   Aymerich, Marta ^a   Rozman, María ^a   Arenillas, Leonor ^a   Esteve, Jordi ^a   Bladé, Joan ^a,b   Montserrat, Emili ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Angiogenesis; Myeloma; Response; Thalidomide

Indexed keywords

ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR 1; INTERLEUKIN 6; SCATTER FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOMODULATION; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 18144450541     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2004.02.002     Document Type: Article

References (29)

1. Singhal S., Metha J., Desican R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1999;1565-1571
2. Juliusson G., Celsing F., Turesson I., Lenhoff S., Adrianson M., Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 109:2000;89-96
3. Kneller A., Raanani P., Hardan A., Avigdor A., Levi I., Berkowicz, et al. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br J Haematol. 108:2000;191-193
4. Yakoub-Agha I., Moreau P., Leyvraz S., Berthou C., Payen C., Dumonter C., et al. Thalidomide in patients with advanced multiple myeloma. Hematol J. 1:2000;186-189
5. Rajkumar S.V., Fonseca R., Dispenzieri A., Lacy M.Q., Lust J.A., Witzig T.E., et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 75:2000;897-901
6. Barlogie B., Desikan R., Addelmon P., Spencer T., Zeldis J., Munshi N., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 98:2001;492-494
7. Bladé J., Esteve J., Rosiñol L., Perales M., Montoto S., Tuset M., et al. Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol. 28:2001;588-592
8. Raje N., Anderson K.C. Thalidomide - a revival story. N Engl J Med. 341:1999;1606-1609
9. Vacca A., Di Loreto M., Ribatti D., Di Stefano R., Gadaleta-Caldarola, Iodice G., et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol. 50:1995;9-14
10. Ribatti D., Vacca A., Nico B., Quondomatteo F., Ria R., Minischetti M., et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Haematol. 79:1999;451-455
11. Vacca A., Ribatti D., Presta M., Minischetti M., Ria R., Albini A., et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 93:1999;3064-3073
12. Leroche M., Broussett P., Ludot I., Mazières, Thiechart M., Attal M. Increased vascularization in myeloma. Eur J Haematol. 66:2001;89-93
13. Sezer O., Jacob C., Eucker J., Niemöller K., Gatz F., Werneche K.D., et al. Serum levels of the angiogenic cytokines basic fibroblastic growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol. 66:2001;83-88
14. Seidel C., Lenhof S., Bravrand S., Anderson G., Standal T., Lang-Nielsen J.L., et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol. 119:2002;672-676
15. Bladé J., Perales M., Rosiñol L., Tuset M., Montoto S., Esteve J., et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol. 113:2001;422-425
16. Biagi J.J., Mileshkin L., Grigg A.P., Westerman D.W., Prince H.M. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant. 42:2001;683-687
17. Bladé J., Samson D., Reece D., Apperley J., Gahrton G., Bjorkstrand B., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hematopoietic stem cell transplantation. Br J Haematol. 102:1998;1115-1123
18. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481
19. Sezer O., Niemoller K., Euker J., Jacob C., Kaufmann O., Zavrski J., et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 79:2000;574-577
20. Iwasaki T., Hamano T., Ogata A., Hashimoto N., Kitano M., Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol. 116:2002;796-802
21. Kumar S., Fonseca R., Dispenzieri A., Lacy M.Q., Lust J.A., Witzig T.E., et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 101:2003;1715-1717
22. Podar K., Tai Y.T., Davies E., Lentzsch, Sattler M., Hedeshima T., et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 98:2001;428-435
23. Anderson K.C. Targeted therapy for multiple myeloma. Semin Haematol. 38:2001;286-294
24. Rajkumar S.V., Fonseca R., Witzig T.E., Gertz M.A., Greipp P.R. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 13:1999;469-472
25. Kumar S., Fonseca R., Dispenzieri A., Lacy M.Q., Lust J.A., Witzig T.E., et al. Bone marrow angiogenesis in multiple myeloma: effects of therapy. Br J Haematol. 119:2002;665-671
26. Di Raimundo F., Azzaro M.P., Palumbo G.A., Bagnato S., Giustolisi G., Floridia P.M., et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica. 85:2000;800-805
27. Neben K., Moechler T., Egerer G., Kraemer A., Hillengass J., Benner A., et al. High plasma basic fibroblastic growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res. 7:2001;2675-2681
28. Neben K., Moehler T., Kraemer A., Benner A., Egerer G., Ho A.D., et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol. 115:2001;605-608
29. Lentzsch S., Leblanc R., Podar K., Davies F., Lin B., Hideshima T., et al. Immunomodulatory analogs to thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 17:2003;41-44